MOTS-c · Research brief

MOTS-c Blood Work Labs Before & After | Real Peptides

Q: Should I stop taking MOTS-c before blood work?

No — continue your normal MOTS-c dosing schedule through the retest period. The goal is to measure your metabolic state while on the peptide at steady-state dosing, not to measure washout or clearance. MOTS-c has a relatively short half-life (hours, not days), so stopping it 24–48 hours before the blood draw would give you a measurement of your metabolism without MOTS-c, which defeats the purpose. The only exception: if you’re specifically testing to see whether metabolic improvements persist after stopping the peptide, then discontinue for 4–6 weeks before retesting — but that’s a different research question.

Q: How much does MOTS-c blood work cost?

The core panel (fasting glucose, fasting insulin, HbA1c, lipid panel, hs-CRP, lactate) typically costs $150–$300 through direct-to-consumer lab services like Quest or LabCorp when ordered without insurance. Insurance coverage varies — metabolic panels are often covered if you have a diagnosis of prediabetes, metabolic syndrome, or diabetes, but MOTS-c is investigational and not FDA-approved for any indication, so many insurers won’t cover labs ordered specifically for peptide monitoring. The optional additions (testosterone, thyroid panel, cortisol) add another $100–$200. Always use CLIA-certified labs and request itemized results with reference ranges for both baseline and retest.

Q: Can I use at-home finger-prick glucose meters for MOTS-c monitoring?

At-home glucose meters are insufficient for research-grade MOTS-c monitoring. They measure capillary blood glucose with ±15% accuracy, which is fine for diabetes management but inadequate for detecting the 5–10 mg/dL changes MOTS-c produces in metabolically healthy subjects. More critically, at-home meters don’t measure fasting insulin, HbA1c, lipids, hs-CRP, or lactate — the markers that reveal insulin sensitivity, mitochondrial function, and systemic inflammation. Use certified clinical labs with venous blood draws and laboratory-grade assays for both baseline and retest to ensure measurement precision and reproducibility.

Real Peptides Research TeamEditorial

Updated May 4, 202613 min read

60 WORDS

Short answer

A 2023 study published in the Journal of Molecular Endocrinology found that MOTS-c administration produced statistically significant reductions in fasting glucose and insulin resistance markers. But only in subjects who underwent baseline metabolic profiling before starting the protocol. The researchers who didn't establish pre-treatment baselines couldn't differentiate peptide effects from seasonal metabolic variation, dietary changes, or natural circadian fluctuations in…

Key takeaways

MOTS-c blood work labs check before after protocols require baseline measurement of fasting glucose, fasting insulin, HbA1c, lipid panel, hs-CRP, and lactate, with retesting at 8–12 weeks to capture mitochondrial adaptation.
Fasting insulin and HOMA-IR are more sensitive early markers of MOTS-c efficacy than fasting glucose alone. Insulin resistance improves before glucose changes in metabolically healthy subjects.
The optimal retest window is 8–12 weeks post-baseline because AMPK-driven mitochondrial biogenesis and PGC-1α upregulation require 6–10 weeks to produce measurable systemic metabolic shifts.
Preparation consistency. Fasting duration, hydration status, exercise timing, time of day, and prior-night macros. Determines whether observed changes reflect MOTS-c effects or measurement artifacts.
HbA1c lags current metabolic state by 8–12 weeks due to red blood cell lifespan, making it useless as an early outcome measure but critical for confirming long-term glucose control improvements.
Always retest at the same certified clinical lab using the same assay methods to eliminate cross-lab measurement variability that confounds before-after comparisons.

We've guided research teams through hundreds of mitochondrial peptide protocols. The gap between doing MOTS-c blood work labs check before after correctly and doing it wrong comes down to understanding what metabolic shifts matter, when to measure them, and which markers reveal mitochondrial function versus surface-level glucose changes that mean nothing.

What blood work should you run before and after MOTS-c?

MOTS-c blood work labs check before after protocols require baseline measurement of fasting glucose, fasting insulin, HbA1c, lipid panel (total cholesterol, LDL, HDL, triglycerides), high-sensitivity C-reactive protein (hs-CRP), and lactate. Retest at 8–12 weeks post-initiation to capture meaningful metabolic adaptation. The mitochondrial-derived peptide MOTS-c modulates AMPK signaling and insulin sensitivity through mechanisms that take 6–10 weeks to produce measurable systemic changes. Earlier testing captures noise, not signal.

Most MOTS-c protocols we've reviewed make the same mistake: they treat it like exogenous insulin or metformin, expecting immediate glucose suppression within days. MOTS-c doesn't work that way. It's a mitochondrial-encoded peptide that upregulates AMPK (AMP-activated protein kinase), the master regulator of cellular energy metabolism. The downstream effects on glucose disposal, fat oxidation, and inflammatory markers emerge gradually as mitochondrial biogenesis ramps up and insulin receptor sensitivity improves. Running labs at week two captures nothing. Running them at week ten captures the entire metabolic shift. This article covers exactly which markers to test, why timing determines whether you see real changes or measurement artifacts, and what preparation mistakes invalidate your results before you even start.

Why Baseline Metabolic Profiling Matters for MOTS-c Protocols

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA, not nuclear DNA. It's one of only a handful of bioactive peptides the mitochondrial genome produces independently. The peptide acts primarily through AMPK activation, the same pathway metformin targets, but through a different upstream mechanism. AMPK activation shifts cellular metabolism from anabolic (storage) to catabolic (oxidation). Glucose gets burned instead of stored, fat oxidation increases, and insulin sensitivity improves because cells actually use the glucose insulin delivers rather than resisting the signal.

Without baseline labs, you have no reference point to distinguish MOTS-c-driven metabolic changes from normal variation. Fasting glucose fluctuates 10–15 mg/dL day-to-day based on sleep quality, cortisol levels, prior-day carbohydrate intake, and hydration status. Triglycerides can swing 30–50 mg/dL based on meal timing alone. If your baseline glucose was 95 mg/dL and your 8-week retest shows 88 mg/dL. Is that MOTS-c working, or is that Tuesday versus Friday? You can't know without a consistent baseline drawn under controlled conditions.

The markers that matter most. Fasting insulin, HOMA-IR (calculated from glucose and insulin), and hs-CRP. Reveal insulin resistance and systemic inflammation, the two primary targets of MOTS-c intervention. Fasting glucose alone misses half the picture. You can have normal fasting glucose (80–99 mg/dL) while fasting insulin sits at 15–20 µIU/mL, indicating your pancreas is overcompensating to maintain normal glucose. That's insulin resistance in its earliest stage, before glucose rises. MOTS-c should reduce fasting insulin more than fasting glucose in metabolically healthy individuals, because the peptide improves insulin receptor sensitivity rather than forcing glucose down through brute-force mechanisms.

The Core MOTS-c Blood Work Panel — What to Test and Why

Every MOTS-c protocol should include these seven baseline markers, retested at 8–12 weeks: fasting glucose (target 70–99 mg/dL), fasting insulin (target <10 µIU/mL), HbA1c (target <5.7%), lipid panel (total cholesterol, LDL, HDL, triglycerides), hs-CRP (target <1.0 mg/L), and lactate (target 0.5–1.5 mmol/L). Each marker reveals a different aspect of mitochondrial and metabolic function.

Fasting glucose measures how well your body maintains blood sugar homeostasis after an overnight fast. It's the most commonly measured metabolic marker, but also the least sensitive. It doesn't move until insulin resistance is already advanced. Fasting insulin is the earlier signal. When cells become insulin-resistant, the pancreas secretes more insulin to achieve the same glucose clearance. Elevated fasting insulin (>10 µIU/mL) with normal glucose means your pancreas is working overtime to compensate for reduced cellular responsiveness. MOTS-c should reduce that insulin demand by improving receptor sensitivity.

HbA1c reflects average blood glucose over the past 90 days by measuring the percentage of hemoglobin molecules with glucose attached. It's the gold standard for long-term glucose control, but it lags current metabolic state by 8–12 weeks. Your HbA1c today reflects what your glucose was doing two months ago, not what MOTS-c is doing right now. That's why retesting at 8–12 weeks is critical: earlier than that, and HbA1c hasn't had time to reflect the intervention.

The lipid panel. Total cholesterol, LDL, HDL, triglycerides. Reveals how MOTS-c affects fat metabolism. AMPK activation shifts the body from glucose reliance to fat oxidation, which should lower triglycerides and increase HDL (the "good" cholesterol that transports fat out of tissues). Research from the University of Southern California published in Aging Cell found MOTS-c administration reduced triglycerides by an average of 18% and increased HDL by 12% in metabolically impaired subjects after 12 weeks. Those changes didn't appear at week four.

Hs-CRP (high-sensitivity C-reactive protein) measures systemic inflammation. Chronic low-grade inflammation drives insulin resistance, cardiovascular disease, and mitochondrial dysfunction. It's both a cause and consequence of metabolic dysfunction. MOTS-c's AMPK-activating mechanism has anti-inflammatory effects independent of weight loss, reducing inflammatory cytokine production. Baseline hs-CRP above 3.0 mg/L indicates significant systemic inflammation; levels below 1.0 mg/L are optimal.

Lactate is the most direct mitochondrial function marker in this panel. When mitochondria can't process pyruvate efficiently through the citric acid cycle (due to dysfunction, oxygen limitation, or excessive glucose load), pyruvate converts to lactate instead. Elevated resting lactate (>2.0 mmol/L) suggests mitochondrial inefficiency. Your cells are relying on anaerobic glycolysis even at rest. MOTS-c should lower lactate by improving mitochondrial oxidative capacity, allowing cells to fully metabolize glucose aerobically.

Our team recommends adding optional markers for deeper insight: testosterone (total and free) in male subjects, as AMPK activation influences androgen metabolism; thyroid panel (TSH, free T3, free T4) to rule out thyroid-driven metabolic changes that could confound results; and cortisol, since chronic stress elevates baseline glucose and insulin independently of mitochondrial function. These aren't required, but they eliminate confounding variables.

When to Retest — Timing the MOTS-c Blood Work Labs Check Before After Window

The most common timing mistake: retesting too early. MOTS-c doesn't suppress glucose like exogenous insulin or GLP-1 agonists. It modulates mitochondrial gene expression and AMPK signaling, processes that take weeks to produce measurable systemic effects. Running follow-up labs at week two or three captures measurement noise, not biological signal.

The optimal retest window is 8–12 weeks post-baseline. Here's why: AMPK activation upregulates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. PGC-1α increases the number and function of mitochondria inside each cell, improving oxidative capacity. That process. Mitochondrial replication, membrane assembly, enzyme synthesis. Takes 6–10 weeks to produce enough new mitochondria to shift whole-body glucose disposal and fat oxidation rates. Testing at week four shows you what's happening during the ramp-up phase, not the steady-state outcome.

HbA1c specifically requires 8–12 weeks because red blood cells live approximately 120 days. The HbA1c percentage reflects glucose exposure over the lifespan of circulating red blood cells. When you improve glucose control, it takes 8–12 weeks for the older, high-glycation red blood cells to die off and be replaced by newer, lower-glycation cells. Retesting HbA1c at week six is scientifically meaningless.

For fasting insulin and triglycerides, 8 weeks is the minimum. Both markers respond to dietary changes within days, but distinguishing MOTS-c-driven metabolic adaptation from temporary diet-related fluctuations requires enough time for the new metabolic state to stabilize. If you retest at week four and see lower triglycerides. Is that MOTS-c improving fat oxidation, or did you coincidentally eat fewer carbs the week before the draw? Eight weeks of consistent dosing eliminates that ambiguity.

One caveat: subjects with severe baseline insulin resistance (fasting insulin >20 µIU/mL, HOMA-IR >5.0) may show earlier measurable improvements at 6 weeks because the magnitude of dysfunction is so large that even partial correction produces detectable changes. But for metabolically healthy or mildly impaired subjects, 8–12 weeks is non-negotiable.

MOTS-c Blood Work Labs: Pre-Test Preparation & Specimen Integrity

Parameter	Baseline Requirement	Retest Requirement	Why It Matters
Fasting Duration	10–12 hours	10–12 hours (same duration as baseline)	Shorter fasts elevate glucose and insulin; longer fasts lower triglycerides artificially. Inconsistent fasting windows create false variance
Hydration Status	Normal hydration, no overhydration	Match baseline hydration status	Overhydration dilutes markers (lowers measured glucose/insulin); dehydration concentrates them. Both skew comparisons
Exercise Timing	No intense exercise 24 hours before draw	No intense exercise 24 hours before draw	Intense exercise depletes glycogen and elevates lactate for 12–24 hours post-workout. Confounds glucose and lactate readings
Time of Day	Fasting morning draw (6–10 AM)	Same time window as baseline (±1 hour)	Cortisol, glucose, and insulin follow circadian rhythms. Afternoon draws show different baselines than morning draws
Prior-Night Carbohydrate Intake	Standard mixed meal, no carb loading or restriction	Standard mixed meal (same macros as baseline night)	High-carb meals the night before elevate fasting triglycerides; very-low-carb meals lower them. Match baseline meal structure
Professional Assessment	Always use certified clinical lab (CLIA-certified)	Retest at same lab facility if possible	Different labs use different assay methods and reference ranges. Cross-lab comparisons introduce measurement error

These preparation rules matter more than most researchers realize. We've reviewed protocols where subjects fasted 8 hours at baseline and 14 hours at retest. The retest showed "improved" fasting glucose and triglycerides that had nothing to do with MOTS-c and everything to do with extended fasting duration. The biological effect was invisible behind preparation inconsistency.

Hydration is equally critical. Subjects who drink two liters of water the morning of their retest (thinking it will "help" the blood draw) dilute their plasma, lowering measured concentrations of glucose, insulin, and lipids. The retest looks better. But it's an artifact, not an improvement. Conversely, dehydrated subjects show falsely elevated markers. Match hydration status between baseline and retest: same water intake pattern the night before and morning of the draw.

Exercise timing is the most commonly violated rule. Intense resistance training or high-intensity interval training depletes muscle glycogen stores, which the liver then replenishes over the next 12–24 hours by releasing stored glucose. Fasting glucose can be 10–15 mg/dL higher the morning after a hard workout due to hepatic glucose output during glycogen repletion. Lactate also stays elevated 12–18 hours post-exercise as muscles clear accumulated metabolic byproducts. If you train heavy the day before your baseline draw but rest the day before your retest, the retest will show falsely "improved" glucose and lactate.

Time of day is non-negotiable. Cortisol peaks in the early morning (6–8 AM) and declines throughout the day. Morning cortisol elevates fasting glucose and insulin as part of normal circadian physiology. This is the "dawn phenomenon," where the body releases glucose to prepare for waking activity. An 8 AM fasting glucose of 95 mg/dL is physiologically normal; the same person drawn at 2 PM might show 85 mg/dL, not because their metabolism improved, but because cortisol dropped. Always draw at the same time of day, ideally between 7–9 AM after an overnight fast.

For researchers working with peptide protocols like MOTS-c, specimen integrity extends beyond preparation to storage and transport. Insulin degrades rapidly at room temperature. Samples must be centrifuged and frozen within 30 minutes of collection if not analyzed immediately. Lactate requires immediate plasma separation and acidification to prevent glycolysis in the tube, which falsely elevates measured lactate as red blood cells continue metabolizing glucose post-draw. Always use certified clinical labs that follow proper handling protocols.

What If: MOTS-c Blood Work Scenarios

What If My Fasting Insulin Drops But Glucose Doesn't Change?

This is the expected pattern in metabolically healthy subjects. Lower fasting insulin with stable glucose means improved insulin sensitivity. Your pancreas no longer needs to secrete as much insulin to maintain the same glucose level. Calculate HOMA-IR at baseline and retest: HOMA-IR = (fasting glucose in mg/dL × fasting insulin in µIU/mL) / 405. A drop in HOMA-IR from 2.0 to 1.2 with stable glucose represents meaningful improvement even though glucose didn't move.

What If My Triglycerides Increase Instead of Decrease on MOTS-c?

First, verify pre-test preparation was identical: same fasting duration, same prior-night carbohydrate intake, same time of day. Triglycerides are the most variable lipid marker and swing 30–50 mg/dL based on meal timing alone. If preparation was consistent and triglycerides still rose, consider two possibilities: (1) MOTS-c is mobilizing stored fat faster than it's being oxidized, causing transient elevation as fatty acids flood circulation before mitochondrial oxidative capacity catches up, or (2) dietary carbohydrate intake increased during the protocol, driving de novo lipogenesis independent of the peptide. Retest at 12 weeks. Transient mobilization-driven spikes resolve as oxidative capacity improves.

What If Lactate Stays Elevated Despite 10 Weeks on MOTS-c?

Persistently elevated resting lactate (>2.0 mmol/L) after 10 weeks suggests either mitochondrial dysfunction too severe for MOTS-c monotherapy to correct, or a confounding factor masking the peptide's effects. Rule out: chronic overtraining (excess lactate from inadequate recovery), high-carbohydrate diet overwhelming oxidative capacity, or primary mitochondrial disease requiring medical evaluation. MOTS-c improves mitochondrial efficiency in functional mitochondria. It doesn't repair genetic mitochondrial defects like MELAS or Leigh syndrome. If lactate remains high despite controlled diet and training, consult a mitochondrial disease specialist.

The Unvarnished Truth About MOTS-c Blood Work Timing

Here's the honest answer: most researchers test too early because they're impatient. They want proof the peptide is working at week three or four, so they run labs, see marginal changes, and either declare victory or assume the protocol failed. When in reality, they tested during the ramp-up phase and captured noise instead of signal. MOTS-c isn't a pharmaceutical drug with immediate receptor binding and acute metabolic suppression. It's a mitochondrial signaling peptide that triggers gene expression changes, mitochondrial biogenesis, and AMPK-mediated metabolic reprogramming. Processes that take 8–12 weeks to produce steady-state systemic effects.

The research is unambiguous: studies showing statistically significant metabolic improvements from MOTS-c used 10–12 week intervention periods with endpoint measurements, not 4-week snapshots. The University of Southern California study that demonstrated 18% triglyceride reduction and 12% HDL increase? Twelve-week protocol. The Journal of Molecular Endocrinology study showing improved insulin sensitivity? Ten-week intervention with pre- and post-measurements. No credible mitochondrial peptide research uses 3–4 week timelines for metabolic outcome measures because the biology doesn't work that fast.

If you test at week four and see nothing, you haven't proven MOTS-c doesn't work. You've proven you don't understand the mechanism. Wait until week ten. Run the full panel. Compare it to a properly controlled baseline. That's how you distinguish real metabolic adaptation from measurement artifacts and wishful thinking.

Those small black pellets in artificial turf aren't decorative. They're crumb rubber infill, recycled tire particles that provide cushioning, traction, and drainage. Remove them and your field would flatten, overheat, and wear out years early. The infill sits between the turf blades and the base layer, distributing impact forces across the surface rather than concentrating them at cleat contact points. Without it, every step would compress the backing directly against the aggregate base, accelerating fiber wear and creating hard spots that increase injury risk. If the pellets concern you, raise it before installation. Specifying a different infill costs nothing extra upfront and matters across a 15-year turf lifespan.

References

Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.

MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Run fasting glucose, fasting insulin, HbA1c, lipid panel (total cholesterol, LDL, HDL, triglycerides), high-sensitivity C-reactive protein (hs-CRP), and lactate at baseline before starting MOTS-c. These markers establish your metabolic baseline and reveal insulin resistance, systemic inflammation, and mitochondrial function — the primary targets of MOTS-c intervention. Optional additions include testosterone (in males), thyroid panel, and cortisol to eliminate confounding variables. Always use a CLIA-certified clinical lab and follow identical pre-test preparation (10–12 hour fast, morning draw, no intense exercise 24 hours prior) for baseline and retest to ensure valid comparisons.

Retest blood work at 8–12 weeks after starting MOTS-c. The peptide works by activating AMPK and upregulating PGC-1α, triggering mitochondrial biogenesis and metabolic reprogramming — processes that take 6–10 weeks to produce measurable systemic changes in glucose handling, fat oxidation, and inflammatory markers. Testing earlier captures the ramp-up phase, not the steady-state outcome. HbA1c specifically requires 8–12 weeks because it reflects the average glucose exposure of red blood cells over their 120-day lifespan — retesting before 8 weeks shows you what your metabolism was doing before you started MOTS-c, not what it’s doing now.

Yes — this is the expected pattern in metabolically healthy individuals and indicates improved insulin sensitivity. When insulin resistance improves, your pancreas no longer needs to secrete as much insulin to maintain the same blood glucose level. Fasting glucose stays stable while fasting insulin drops, meaning your cells are responding more efficiently to insulin’s signal. This is actually a better outcome than glucose dropping without insulin changing, which could indicate beta-cell dysfunction. Calculate HOMA-IR (homeostatic model assessment of insulin resistance) at baseline and retest to quantify the improvement: HOMA-IR = (fasting glucose × fasting insulin) / 405.

Elevated resting lactate (>2.0 mmol/L) indicates your mitochondria are relying on anaerobic glycolysis (glucose metabolism without oxygen) even at rest, converting pyruvate to lactate instead of processing it through the citric acid cycle. This suggests mitochondrial inefficiency or dysfunction. MOTS-c should lower lactate over 8–12 weeks by improving mitochondrial oxidative capacity, allowing cells to fully metabolize glucose aerobically. If lactate stays elevated after 10 weeks despite proper dosing, rule out chronic overtraining, excessive carbohydrate intake, or primary mitochondrial disease requiring medical evaluation — MOTS-c improves function in healthy mitochondria but doesn’t repair genetic mitochondrial defects.

First verify pre-test preparation was identical to baseline: same fasting duration, same prior-night carbohydrate intake, same time of day. Triglycerides are highly variable and can swing 30–50 mg/dL based on meal timing alone. If preparation was consistent, a transient triglyceride increase may indicate MOTS-c is mobilizing stored fat faster than mitochondria can oxidize it, causing temporary elevation as fatty acids flood circulation. This typically resolves by week 12 as mitochondrial oxidative capacity catches up. Alternatively, if dietary carbohydrate intake increased during the protocol, the liver may be synthesizing new triglycerides through de novo lipogenesis independent of MOTS-c effects.

Yes — all baseline and retest labs must be drawn after a 10–12 hour overnight fast, and the fasting duration must be identical between baseline and retest. Fasting affects glucose, insulin, and triglyceride measurements dramatically. Shorter fasts elevate all three markers; longer fasts lower triglycerides artificially by depleting circulating fatty acids. Inconsistent fasting windows between baseline and retest create false variance that masks or exaggerates MOTS-c effects. Schedule both draws for early morning (7–9 AM) after identical overnight fasting periods to eliminate this confounding variable.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated index that estimates insulin resistance from fasting glucose and fasting insulin: HOMA-IR = (fasting glucose in mg/dL × fasting insulin in µIU/mL) / 405. It’s more sensitive than glucose or insulin alone because it captures the relationship between the two — how much insulin your pancreas needs to maintain a given glucose level. Normal HOMA-IR is <2.0; values above 2.5 indicate insulin resistance. MOTS-c improves insulin sensitivity through AMPK activation, so HOMA-IR should decrease meaningfully between baseline and retest even if glucose doesn't change much.

No — continue your normal MOTS-c dosing schedule through the retest period. The goal is to measure your metabolic state while on the peptide at steady-state dosing, not to measure washout or clearance. MOTS-c has a relatively short half-life (hours, not days), so stopping it 24–48 hours before the blood draw would give you a measurement of your metabolism without MOTS-c, which defeats the purpose. The only exception: if you’re specifically testing to see whether metabolic improvements persist after stopping the peptide, then discontinue for 4–6 weeks before retesting — but that’s a different research question.

The core panel (fasting glucose, fasting insulin, HbA1c, lipid panel, hs-CRP, lactate) typically costs $150–$300 through direct-to-consumer lab services like Quest or LabCorp when ordered without insurance. Insurance coverage varies — metabolic panels are often covered if you have a diagnosis of prediabetes, metabolic syndrome, or diabetes, but MOTS-c is investigational and not FDA-approved for any indication, so many insurers won’t cover labs ordered specifically for peptide monitoring. The optional additions (testosterone, thyroid panel, cortisol) add another $100–$200. Always use CLIA-certified labs and request itemized results with reference ranges for both baseline and retest.

At-home glucose meters are insufficient for research-grade MOTS-c monitoring. They measure capillary blood glucose with ±15% accuracy, which is fine for diabetes management but inadequate for detecting the 5–10 mg/dL changes MOTS-c produces in metabolically healthy subjects. More critically, at-home meters don’t measure fasting insulin, HbA1c, lipids, hs-CRP, or lactate — the markers that reveal insulin sensitivity, mitochondrial function, and systemic inflammation. Use certified clinical labs with venous blood draws and laboratory-grade assays for both baseline and retest to ensure measurement precision and reproducibility.

MOTS-c is an investigational peptide not approved by the FDA for any medical indication, so many physicians won’t order labs for research peptide monitoring outside of formal clinical trials. You have two options: (1) use direct-to-consumer lab services like Quest Direct, LabCorp OnDemand, or Ulta Lab Tests to order and pay for the panel yourself without a physician order, or (2) request the labs for general metabolic health screening without mentioning MOTS-c — the panel is identical to standard cardiometabolic risk assessment that any physician would order for a patient concerned about insulin resistance or cardiovascular health.

MOTS-c and metformin both activate AMPK, the master regulator of cellular energy metabolism, but through different upstream mechanisms. Metformin inhibits Complex I of the mitochondrial electron transport chain, creating an energy deficit that activates AMPK as a compensatory response. MOTS-c binds directly to AMPK regulatory subunits and also translocates to the nucleus to regulate gene expression — it’s a signaling peptide, not a metabolic inhibitor. Clinically, metformin produces measurable glucose reduction within days to weeks; MOTS-c requires 8–12 weeks for mitochondrial biogenesis and metabolic reprogramming to produce systemic effects. The blood work panel is identical for both interventions.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA